These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer. Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642 [TBL] [Abstract][Full Text] [Related]
3. [Urinary cytology in cases of bladder cancer: a critical evaluation]. Rathert P Urologe A; 2003 Jul; 42(7):908-11. PubMed ID: 12898033 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract. Konety BR; Metro MJ; Melham MF; Salup RR Urol Int; 1999; 62(1):26-30. PubMed ID: 10436427 [TBL] [Abstract][Full Text] [Related]
5. [Diagnostic value of the BRAF variant V595E in urine samples, smears and biopsies from canine transitional cell carcinoma]. Aupperle-Lellbach H; Grassinger J; Hohloch C; Kehl A; Pantke P Tierarztl Prax Ausg K Kleintiere Heimtiere; 2018 Oct; 46(5):289-295. PubMed ID: 30541168 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of a bladder tumor antigen test as a screening test for transitional cell carcinoma of the lower urinary tract in dogs. Henry CJ; Tyler JW; McEntee MC; Stokol T; Rogers KS; Chun R; Garrett LD; McCaw DL; Higginbotham ML; Flessland KA; Stokes PK Am J Vet Res; 2003 Aug; 64(8):1017-20. PubMed ID: 12926595 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer. Lee KH Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder. Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007 [TBL] [Abstract][Full Text] [Related]
9. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. Shariat SF; Casella R; Monoski MA; Sulser T; Gasser TC; Lerner SP J Urol; 2003 Dec; 170(6 Pt 1):2244-7. PubMed ID: 14634389 [TBL] [Abstract][Full Text] [Related]
10. BTA-TRAK combined with urinary cytology is a reliable urinary indicator of recurrent transitional cell carcinoma (TCC) of the bladder. Mattioli S; Seregni E; Caperna L; Botti C; Savelli G; Bombardieri E Int J Biol Markers; 2000; 15(3):219-25. PubMed ID: 11012097 [TBL] [Abstract][Full Text] [Related]
11. Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence. Kundal VK; Pandith AA; Hamid A; Shah A; Kundal R; Wani SM Asian Pac J Cancer Prev; 2010; 11(5):1279-82. PubMed ID: 21198277 [TBL] [Abstract][Full Text] [Related]
13. [Non-invasive urinary diagnosis of bladder cancer. What do we know?]. Kausch I; Böhle A Urologe A; 2003 Jul; 42(7):912-21. PubMed ID: 12898034 [TBL] [Abstract][Full Text] [Related]
14. Urinary markers in the everyday diagnosis of bladder cancer. Dal Moro F; Valotto C; Guttilla A; Zattoni F Urologia; 2013; 80(4):265-75. PubMed ID: 24419920 [TBL] [Abstract][Full Text] [Related]
15. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment. Bartoletti R; Dal Canto M; Cai T; Piazzini M; Travaglini F; Gavazzi A; Rizzo M Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429 [TBL] [Abstract][Full Text] [Related]
16. NMR-based metabolomics study of canine bladder cancer. Zhang J; Wei S; Liu L; Nagana Gowda GA; Bonney P; Stewart J; Knapp DW; Raftery D Biochim Biophys Acta; 2012 Nov; 1822(11):1807-14. PubMed ID: 22967815 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. Stampfer DS; Carpinito GA; Rodriguez-Villanueva J; Willsey LW; Dinney CP; Grossman HB; Fritsche HA; McDougal WS J Urol; 1998 Feb; 159(2):394-8. PubMed ID: 9649246 [TBL] [Abstract][Full Text] [Related]
18. Clinical utility of urinary soluble Fas in screening for bladder cancer. Srivastava AK; Singh PK; Singh D; Dalela D; Rath SK; Bhatt ML Asia Pac J Clin Oncol; 2016 Jun; 12(2):e215-21. PubMed ID: 24576318 [TBL] [Abstract][Full Text] [Related]
19. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. Soloway MS; Briggman V; Carpinito GA; Chodak GW; Church PA; Lamm DL; Lange P; Messing E; Pasciak RM; Reservitz GB; Rukstalis DB; Sarosdy MF; Stadler WM; Thiel RP; Hayden CL J Urol; 1996 Aug; 156(2 Pt 1):363-7. PubMed ID: 8683680 [TBL] [Abstract][Full Text] [Related]
20. Results of biopsy via transurethral cystoscopy and cystotomy for diagnosis of transitional cell carcinoma of the urinary bladder and urethra in dogs: 92 cases (2003-2008). Childress MO; Adams LG; Ramos-Vara JA; Freeman LJ; He S; Constable PD; Knapp DW J Am Vet Med Assoc; 2011 Aug; 239(3):350-6. PubMed ID: 21801049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]